TW200617396A - Method - Google Patents

Method

Info

Publication number
TW200617396A
TW200617396A TW094133265A TW94133265A TW200617396A TW 200617396 A TW200617396 A TW 200617396A TW 094133265 A TW094133265 A TW 094133265A TW 94133265 A TW94133265 A TW 94133265A TW 200617396 A TW200617396 A TW 200617396A
Authority
TW
Taiwan
Prior art keywords
egfr
isoleucine
seq
patient
sequence
Prior art date
Application number
TW094133265A
Other languages
English (en)
Chinese (zh)
Inventor
Gillian Ellison
Ruth Eleanor March
Alan Wookey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0422158A external-priority patent/GB0422158D0/en
Priority claimed from GB0508493A external-priority patent/GB0508493D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200617396A publication Critical patent/TW200617396A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW094133265A 2004-10-06 2005-09-26 Method TW200617396A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0422158A GB0422158D0 (en) 2004-10-06 2004-10-06 Method
GB0508493A GB0508493D0 (en) 2005-04-27 2005-04-27 Method

Publications (1)

Publication Number Publication Date
TW200617396A true TW200617396A (en) 2006-06-01

Family

ID=35453337

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094133265A TW200617396A (en) 2004-10-06 2005-09-26 Method

Country Status (2)

Country Link
TW (1) TW200617396A (fr)
WO (1) WO2006037994A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506670D0 (en) * 2005-04-01 2005-05-11 Astrazeneca Ab Method
CN106755297A (zh) * 2016-11-15 2017-05-31 上海派森诺医学检验所有限公司 一组基于arms荧光定量pcr检测egfr基因t790m突变的引物组及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733056B1 (fr) * 2004-03-31 2013-05-22 The General Hospital Corporation Procede permettant de determiner la reponse d'un cancer a des traitements cibles par le recepteur du facteur de croissance epidermique

Also Published As

Publication number Publication date
WO2006037994A2 (fr) 2006-04-13
WO2006037994A3 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
NL301089I2 (nl) imlifidase
NO20063624L (no) FC region varianter
WO2008088854A3 (fr) Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie
ATE540696T1 (de) Erbb2-antagonisten für die tumorschmerztherapie
ATE523786T1 (de) In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens
NZ610734A (en) Human antibodies to the glucagon receptor
DK2005162T3 (da) Screeningsmetode
BRPI0819018A2 (pt) "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf"
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
WO2008012362A3 (fr) Nouvelles protéines isoformes et leur utilisation
EP1652923A4 (fr) Gene surexprime dans le cancer
WO2006078853A3 (fr) Proteine d'interaction avec la thioredoxine (txnip) en tant que regulateur de la fonction vasculaire
TW200617396A (en) Method
WO2005112568A3 (fr) Marqueurs haplotypes et procedes d'utilisation de ceux-ci pour determiner la reponse a un traitement
NZ593392A (en) Biomarker for detecting bladder cancer
SE0300959D0 (sv) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
WO2005007871A3 (fr) Marqueur genetique de reponse a des antipsychotiques atypiques et a des antidepresseurs et leurs methodes d'utilisation
WO2008048902A3 (fr) Procédés d'utilisation de polymorphismes nucléotidiques simples dans le gène il23r pour prévoir ou diagnostiquer une maladie intestinale inflammatoire
DE602005016290D1 (de) Glichkeit
TW200720440A (en) Method
ATE486286T1 (de) Prognoseverfahren für kongestives herzversagen
WO2007128984A3 (fr) Marqueurs de cancer du sein
ATE521893T1 (de) P66-shc als prädiktiver marker bei der krebsbehandlung
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy